Quintiles and investor TPG Capital declined to comment on rumours the CRO is sizing up banks and preparing for an IPO.

The speculation began last week when Bloomberg reported that TPG Capital and Bain Capital LLC are interviewing banks to handle the initial public offering (IPO) for Quintiles. Similarly, Reuters reported that the privately-owned contract research organisation (CRO) was speaking to JPMorgan Chase and Deutsche Bank.

Quintiles spokesman Phil Bridges emailed Outsourcing-pharma.com his standard response to questions about the CRO's finances, telling us that: "Quintiles routinely evaluates its capital strategy, and it is our policy not to comment on these matters."

Owen Blicksilver, public relations representative for TPG, was similarly tight-lipped when asked if he could confirm whether or not the CRO was in discussions about going public.

“Sorry… no. You would need to call the company” was his response.

More than a rumour?

Quintiles has been private since 2003 and counts - in addition to Bain and TPG - 3i Group and Temasek Holdings among its investors. The CRO has been rumoured to have close to going public several times
over the last decade, but nothing concrete has ever emerged.

Whether the latest speculation is any more accurate than the previous rumours remains to be seen, but such a move would fit with a number of investor-focused financial steps the firm has taken in recent months.

In December Quintiles secured a $2bn loan
that – according to ratings agency Standard & Poor’s (S&P) – was designed to cut interest rates on debts and pay dividends to investors.

At the time S&P said: “The new loans reduce interest expense and provide for further pricing step downs if Quintiles completes an initial public offering. However, we have no information from the company to suggest that an offering is imminent.”

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below:

Research study

30-Mar-2015 - The increasing challenges in delivering patient enrolment, treatment and retention in clinical trials exist in all Therapeutic Areas but are particularly acute in Prodromal and early symptomatic Alzheimer’s disease. The traditional model of opening ever increasing numbers of sites across...